Employing MeRLin in a melanoma model that recapitulates the clinical emergence of BRAF/MEK inhibitor (BRAFi/MEKi) resistance, we traced the clonal origins and transcriptional states of thousands of individual melanoma cells as they acquired resistance in vivo. This evidence concerns the gene NF2 and melanoma.